How to buy Glaukos stock (GKOS)

Glaukos is a medical devices business based in the US. Glaukos shares (GKOS) are listed on the NYSE and all prices are listed in US Dollars. Its last market close was $150.88 – an increase of 8.6% over the previous week. Glaukos employs 907 staff and has a trailing 12-month revenue of around $360.3 million.

Our top picks for where to buy Glaukos stock

Buy Glaukos stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Glaukos stock price (NYSE: GKOS)

Use our graph to track the performance of GKOS stocks over time.

Glaukos shares at a glance

• Key figures

Information last updated 2024-12-19.

Latest market close	$150.88
52-week range	$74.75 - $148.67
50-day moving average more info button	$136.69
200-day moving average more info button	$118.53
Wall St. target price	$147.25
PE ratio more info button	N/A
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	$-2.93

Is it a good time to buy Glaukos stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Glaukos price performance over time

Historical closes compared with the close of $143.74 from 2024-12-19

1 week (2024-12-13)	3.46%
1 month (2024-11-21)	2.07%
3 months (2024-09-20)	12.49%
6 months (2024-06-21)	27.18%

1 year (2023-12-21)	68.89%
2 years (2022-12-21)	229.83%
3 years (2021-12-21)	220.63%
5 years (2019-12-20)	159.93%

Is Glaukos stock undervalued or overvalued?

Valuing Glaukos stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Glaukos's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Glaukos's PEG ratio

Glaukos's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.64. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Glaukos's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

Glaukos financials

Revenue TTM	$360.3 million
Gross profit TTM	$213.9 million
Return on assets TTM	-7.74%
Return on equity TTM	-26.1%
Profit margin	-41.51%
Book value	$12.13
Market Capitalization more info button	$8 billion

TTM: trailing 12 months

Glaukos share dividends

We're not expecting Glaukos to pay a dividend over the next 12 months.

Glaukos share price volatility

Over the last 12 months, Glaukos's shares have ranged in value from as little as $74.745 up to $148.67. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Glaukos's is 1.028. This would suggest that Glaukos's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).

Glaukos overview

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and surgical therapy; and iDose TR, an intracameral procedural pharmaceutical therapy indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in Aliso Viejo, California. .

Frequently asked questions

null
What percentage of Glaukos is owned by insiders or institutions?
Currently 3.193% of Glaukos shares are held by insiders and 101.201% by institutions. How many people work for Glaukos?
Latest data suggests 907 work at Glaukos. When does the fiscal year end for Glaukos?
Glaukos's fiscal year ends in December. Where is Glaukos based?
Glaukos's address is: One Glaukos Way, Aliso Viejo, CA, United States, 92656 What is Glaukos's ISIN number?
Glaukos's international securities identification number is: US3773221029 What is Glaukos's CUSIP number?
Glaukos's Committee on Uniform Securities Identification Procedures number is: 377322102